J Clin Psychiatry November 2017 PMID 28252882

Effectiveness of Supplementary Cognitive-Behavioral Therapy for Pharmacotherapy-Resistant Depression: A Randomized Controlled Trial.

Atsuo Nakagawa, Dai Mitsuda, Mitsuhiro Sado, Takayuki Abe, Daisuke Fujisawa, Toshiaki Kikuchi, Satoru Iwashita, Masaru Mimura, Yutaka Ono

Full text PDF Download social card

Mentions

Peak: 2 in Jul 2017

across 3 sources since Jul 2017

Extended reach

21,004

potential audience

Total likes

338

Video views

16,577

Mentions per month

Jul 2017 – Apr 2025

Where it's discussed

Facebook9 posts
X / Twitter4 posts
YouTube4 videos

AI synopsis

What people are saying

The discussions reflect a general acknowledgment of the study's findings, with phrases like 'find out' and questions about chemical causes showing curiosity and relevance. The tone is informational but not deeply analytical, indicating interest and moderate engagement, while the emphasis on therapy's effectiveness hints at potential influence on understanding depression treatments.

AgreementModerate agreement

Most posts acknowledge the study's findings that adding CBT benefits treatment-resistant depression, aligning with the article's conclusions.

InterestModerate interest

Posts express some curiosity about the underlying causes of depression and the potential effectiveness of CBT, indicating moderate interest.

EngagementNeutral engagement

Discussions are fairly surface-level, with some posts referencing general concepts like chemical imbalances and therapy, but lacking deep analysis.

ImpactModerate impact

The discussions suggest the research could influence personal treatment choices or raise awareness about therapy options, indicating moderate impact.

Abstract in brief

The study investigated whether adding cognitive-behavioral therapy (CBT) to usual medication management improves outcomes for patients with depression that does not respond to antidepressants alone.
Over 16 weeks, patients receiving combined CBT and treatment as usual showed significantly greater reduction in depressive symptoms compared to those receiving only treatment as usual, and this improvement lasted at least 12 months.
The trial involved 80 patients aged 20-65 with treatment-resistant depression, and the primary measure of success was the change in depression severity scores, with results favoring the addition of CBT.

Read the full abstract